M&A Deal Summary |
|
|---|---|
| Date | 2019-09-17 |
| Target | RoverMed BioSciences |
| Sector | Life Science |
| Buyer(s) | AskBio |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2001 |
| Sector | Life Science |
Asklepios BioPharmaceutical, Inc. is a clinical-stage gene therapy platform company dedicated to improving the lives of children and adults with rare genetic disorders. AskBio’s gene therapy platform includes an industry-leading proprietary cell line manufacturing process known as Pro10TM and an extensive AAV capsid library. AskBio maintains a portfolio of clinical programs across a range of indications including Pompe, Limb-Girdle Muscular Dystrophy, Cystic Fibrosis, Myotonic Muscular Dystrophy, Hemophilia (Chatham Therapeutic/Takeda) and Duchenne Muscular Dystrophy (Bamboo Therapeutics/Pfizer). AskBio was established in 2001 and is based in Research Triangle Park, North Carolina.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| Country: United States M&A | 1 of 1 |
| Year: 2019 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-08-13 |
Synpromics
Edinburgh, United Kingdom Synpromics Ltd. engages in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics, and intelligent data-driven design. Synpromics Ltd. has developed PromPT, its multi-dimensional bioinformatics database, that enables product-specific promoter design and selection empowering the next generation of cell and gene-based medicines and bioprocessing applications. |
Buy | - |
